My watch list
my.bionity.com  
Login  

Abnova and Clearbridge BioMedics Accelerate Circulating Tumor Cell System into the Research and In Vitro Diagnostic Markets

19-Sep-2011

Abnova Corporation and Clearbridge BioMedics announced a collaboration to jointly develop a platform that provides a next generation, non-invasive “liquid biopsy” for cancer screening, staging, treatment, and monitoring. Through this collaboration, Abnova will leverage upon Clearbridge BioMedics’ core ClearCell™ CTChip®, which is an advanced microfiltration system for the isolation, enumeration, and retrieval of viable circulating tumor cells (CTCs) from blood. Abnova will then incorporate its proprietary antibody reagents (both research-grade antibody reagents and cGMP clinical-grade antibodies), to enable the accurate diagnosis of specific medical conditions or diseases.

“CTCs represent one of three important pillars of system integration for Abnova in the hierarchical organization and interrogation of tissue, cell, and protein,” said Dr. Wilber Huang, President and CEO of Abnova. “Clearbridge BioMedics has elegantly engineered a breakthrough CTC platform, which is unmatched by the competitors, specifically the ability to preserve cell viability after isolation. Up until now, the access to tissue samples is confined to the initial biopsy for diagnosis and staging workup followed by pathological confirmation of resected tissues. The opportunity for non-invasive “liquid biopsy” has tremendous potential in disease management, especially in molecular staging, personalized therapy and recurrence monitoring. Abnova has a plethora of research antibodies and FISH probes to catapult the research market, in addition to a full pipeline of novel IVD biomarkers under development, which are applicable to CTC platform including prostate, ovarian, and lung cancers."

Facts, background information, dossiers
More about Abnova
  • News

    Olink Bioscience and Abnova signs co-marketing agreement to promote unique target-specific assays for cell signaling studies

    Olink Bioscience and Abnova Corporation announced a co-development and co-marketing agreement. This collaboration will address the unmet need for high-performance assays for studies of protein phosphorylation and protein interactions by combining Abnova´s growing collection of antibodies wi ... more

  • Companies

    Abnova Corporation

    Abnova is the world's largest antibody manufacturer. We have a capacity of generating 500 mouse monoclonal antibodies per month. Rather than the traditional method of monoclonal antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to h ... more

    Abnova GmbH

    Abnova is the world largest monoclonal antibody manufacturer. We have a capacity of generating 500 mouse monoclonal antibodies per month. Rather than the traditional method of monoclonal antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goa ... more

More about Clearbridge BioMedics
  • News

    Clearbridge BioMedics makes a big impact at the 2012 Asian Innovation Awards

    Clearbridge BioMedics won the top three awards at Asian Innovation Awards 2012. Clearbridge BioMedics took the grand prize for The Asian Innovation Awards 2012, which recognises innovations that break conventional processes to improve quality of life or productivity. Clearbridge BioMedics a ... more

    Clearbridge BioMedics wins Asian Entrepreneurship Award in Japan

    Clearbridge BioMedics has won the 2012 Asian Entrepreneurship Awards, which was held from 9-11 May 2012 in Kashiwanoha, Chiba Prefecture in Japan. A total of 18 start-up companies, from 12 Asian countries presented their business plans at this inaugural business competition. Clearbridge Bio ... more

    Clearbridge BioMedics achieves ISO 13485 certification

    Clearbridge BioMedics has achieved ISO 13485 certification for the development of cell-based in-vitro diagnostic devices and launched its ClearCell System, for the cancer research market. “Through our ClearCell™ System, we are now entering the diverse and growing cancer research market. Thi ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE